TPM1 (Tropomyosin 1) encodes the alpha-isoform of tropomyosin, an actin-binding protein critical for cytoskeletal organization in both muscle and non-muscle cells.
TPM1 Protein (Tropomyosin 1) is the alpha-isoform of the tropomyosin family of actin-binding proteins. It plays a critical role in stabilizing actin filaments and regulating cytoskeletal dynamics. In neurons, TPM1 contributes to axonal transport and synaptic function.
| Attribute |
Value |
| Protein Name |
Tropomyosin-1 |
| Gene |
TPM1 |
| UniProt ID |
P09493 |
| PDB Structure |
1C1G, 1TXK, 2D3E |
| Molecular Weight |
~32.7 kDa |
| Subcellular Localization |
Cytoskeleton, Thin filaments (muscle) |
| Protein Family |
Tropomyosin family |
Tropomyosin-1 is a coiled-coil protein that forms a dimer:
- Coiled-Coil Domain: Two alpha-helical chains wound around each other
- Actin-Binding Sites: Multiple sites along the dimer for actin interaction
- Isoform Variants: Multiple isoforms generated by alternative splicing
- N-terminal Region: Critical for actin binding and polymerization
The protein forms a continuous polymer along actin thin filaments, with head-to-tail polymerization providing cooperative binding.
- Actin Filament Stabilization: Tropomyosin binds along actin filaments, stabilizing them against depolymerization
- Modulation of Filament Properties: Different isoforms confer different functional properties to actin filaments
- Regulation of Actin-Myosin Interaction: Controls access of myosin heads to actin in muscle cells
- Intracellular Transport: Facilitates vesicle and organelle movement along actin filaments
- Cell Shape and Motility: Maintains cell morphology and enables cell migration
- Stress Response: Involved in cellular responses to mechanical stress
In skeletal and cardiac muscle:
- Thin Filament Component: Core component of the thin filament regulatory system
- Contraction Regulation: Works with troponin complex to regulate muscle contraction
- Calcium Sensitivity: Tropomyosin position determines calcium sensitivity of contraction
TPM1 mutations have been identified in some ALS cases:
- May disrupt cytoskeletal dynamics in motor neurons
- Altered actin filament properties could impair axonal transport
- Potential role in maintaining motor neuron integrity
TPM1 mutations are a well-established cause of:
- Hypertrophic Cardiomyopathy (HCM): Characterized by left ventricular hypertrophy
- Dilated Cardiomyopathy (DCM): Leads to heart failure
- Restrictive Cardiomyopathy: Impaired ventricular filling
Altered TPM1 expression has been reported in various cancers:
- Often downregulated in breast, colorectal, and other cancers
- May affect cell motility and metastasis
Current therapeutic approaches include:
- Direct Targeting: No direct TPM1-targeted drugs currently approved
- Cytoskeletal Stabilizers: Compounds that stabilize actin filaments
- Gene Therapy: Potential for future gene replacement approaches
- Barber et al., TPM1 mutations in cardiomyopathy (2009)
- Gunning et al., Tropomyosin isoform function (2018)
- Reid et al., Tropomyosin and ALS (2013)